Loading...
•
Dec 31, 2020
Alector Q4 2020 Earnings Report
Alector reported Q4 2020 financial results and provided a business update.
Key Takeaways
Alector reported collaboration revenue of $4.9 million for the quarter ended December 31, 2020, compared to $6.0 million for the same period in 2019. The company's net loss was $52.2 million, compared to a net loss of $30.5 million for the same period in 2019. Cash, cash equivalents, and marketable securities were $413.3 million as of December 31, 2020.
Initiated AL001 INFRONT-3 Phase 3 trial in people with frontotemporal dementia with a progranulin mutation; pipeline expansion to ALS planned for 2021
Initiated AL002 INVOKE-2 Phase 2 trial in early Alzheimer’s disease patients
Completed enrollment in the AL003 Phase 1 trial in Alzheimer’s disease patients.
Strong balance sheet continues to support execution of clinical, research and operational goals
Revenue by Segment
Forward Guidance
Alector believes that its cash and investments as of December 31, 2020, will be sufficient to fund its anticipated operations through mid-2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...